These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 38281279)
1. PARP-2 mediates cardiomyocyte aging and damage induced by doxorubicin through SIRT1 Inhibition. Huang C; Zhang X; Wang S; Shen A; Xu T; Hou Y; Gao S; Xie Y; Zeng Y; Chen J; Lin R; Zhang Y; Wan C; Cai Y Apoptosis; 2024 Jun; 29(5-6):816-834. PubMed ID: 38281279 [TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction. Szántó M; Rutkai I; Hegedus C; Czikora Á; Rózsahegyi M; Kiss B; Virág L; Gergely P; Tóth A; Bai P Cardiovasc Res; 2011 Dec; 92(3):430-8. PubMed ID: 21921080 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy. Xia P; Liu Y; Chen J; Coates S; Liu DX; Cheng Z J Biol Chem; 2018 Dec; 293(51):19672-19685. PubMed ID: 30361442 [TBL] [Abstract][Full Text] [Related]
4. Protection against Doxorubicin-Related Cardiotoxicity by Jaceosidin Involves the Sirt1 Signaling Pathway. Liu Y; Zhou L; Du B; Liu Y; Xing J; Guo S; Li L; Chen H Oxid Med Cell Longev; 2021; 2021():9984330. PubMed ID: 34422218 [TBL] [Abstract][Full Text] [Related]
5. Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1 - mediated mitochondrial dysfunction. Zhuang X; Sun X; Zhou H; Zhang S; Zhong X; Xu X; Guo Y; Xiong Z; Liu M; Lin Y; Zhang M; Liao X Mech Ageing Dev; 2021 Apr; 195():111442. PubMed ID: 33539906 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-22 inhibition prevents doxorubicin-induced cardiotoxicity via upregulating SIRT1. Xu C; Liu CH; Zhang DL Biochem Biophys Res Commun; 2020 Jan; 521(2):485-491. PubMed ID: 31677784 [TBL] [Abstract][Full Text] [Related]
7. AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis. Liu D; Ma Z; Di S; Yang Y; Yang J; Xu L; Reiter RJ; Qiao S; Yuan J Free Radic Biol Med; 2018 Dec; 129():59-72. PubMed ID: 30172748 [TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways. Wang A J; Zhang J; Xiao M; Wang S; Wang B J; Guo Y; Tang Y; Gu J Cell Mol Life Sci; 2021 Apr; 78(7):3105-3125. PubMed ID: 33438055 [TBL] [Abstract][Full Text] [Related]
9. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress. Yang N; Ma H; Jiang Z; Niu L; Zhang X; Liu Y; Wang Y; Cheng S; Deng Y; Qi H; Wang Z Biochem Biophys Res Commun; 2019 Sep; 517(1):111-117. PubMed ID: 31303273 [TBL] [Abstract][Full Text] [Related]
10. Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin-related cardiotoxicity. Xia W; Chen H; Yang H; Zhu L; Xie C; Hou M FEBS J; 2024 Sep; 291(18):4029-4042. PubMed ID: 38857187 [TBL] [Abstract][Full Text] [Related]
11. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372 [TBL] [Abstract][Full Text] [Related]
12. Evidences for the mechanism of Shenmai injection antagonizing doxorubicin-induced cardiotoxicity. Wu YP; Zhang S; Xin YF; Gu LQ; Xu XZ; Zhang CD; You ZQ Phytomedicine; 2021 Jul; 88():153597. PubMed ID: 34111614 [TBL] [Abstract][Full Text] [Related]
13. Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte. Kumar SN; Konorev EA; Aggarwal D; Kalyanaraman B J Proteomics; 2011 May; 74(5):683-97. PubMed ID: 21338723 [TBL] [Abstract][Full Text] [Related]
14. Time course of cardiomyopathy induced by doxorubicin in rats. Medeiros-Lima DJM; Carvalho JJ; Tibirica E; Borges JP; Matsuura C Pharmacol Rep; 2019 Aug; 71(4):583-590. PubMed ID: 31174019 [TBL] [Abstract][Full Text] [Related]
15. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress. Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254 [TBL] [Abstract][Full Text] [Related]
16. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. Pacher P; Liaudet L; Bai P; Virag L; Mabley JG; Haskó G; Szabó C J Pharmacol Exp Ther; 2002 Mar; 300(3):862-7. PubMed ID: 11861791 [TBL] [Abstract][Full Text] [Related]
17. Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress. Lin J; Fang L; Li H; Li Z; Lyu L; Wang H; Xiao J Eur J Pharmacol; 2019 Sep; 859():172490. PubMed ID: 31229536 [TBL] [Abstract][Full Text] [Related]
19. Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1. Sun Z; Lu W; Lin N; Lin H; Zhang J; Ni T; Meng L; Zhang C; Guo H Biochem Pharmacol; 2020 May; 175():113888. PubMed ID: 32112883 [TBL] [Abstract][Full Text] [Related]
20. Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2. Wang A J; Tang Y; Zhang J; Wang B J; Xiao M; Lu G; Li J; Liu Q; Guo Y; Gu J Redox Biol; 2022 Jun; 52():102310. PubMed ID: 35452917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]